{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":2980,"total_is_capped":false,"direct_labels_cover":12,"predictions_cover":2980,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"6147ccd71970","filters":{"topic":"Cancer Immunotherapy and Biomarkers"}},"results":[{"id":"W2527905628","doi":"10.1056/nejmoa1606774","title":"Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10101,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Internal medicine; Hazard ratio; Oncology; Chemotherapy; Cancer; Gastroenterology; Confidence interval; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.01779133937735275,"gpt":0.3044793150951555,"spread":0.2866879757178028,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005723452,0.0002159758,0.000585783,0.000177865,0.00005823892,0.00000744731,0.000148564,0.0001022163,0.0008154823],"category_scores_gemma":[0.0001079538,0.0001115699,0.0002077982,0.0001455138,0.0001200846,0.00008211123,0.000009250748,0.0001848299,0.000001795194],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002622257,"about_ca_system_score_gemma":0.0005432774,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001695969,"about_ca_topic_score_gemma":0.00005081616,"domain_scores_codex":[0.9985745,0.00003591415,0.0005381521,0.0001760255,0.0003731181,0.0003023132],"domain_scores_gemma":[0.99835,0.0004317825,0.000400198,0.0001812927,0.0003375216,0.0002991781],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1490018,0.0001285703,0.003028722,0.0001408678,0.001028348,0.00009506211,0.001755989,0.000001747863,0.2072444,0.00001950355,0.0667982,0.5707568],"study_design_scores_gemma":[0.7013577,0.01042218,0.01401882,0.003090828,0.001128806,0.0005931967,0.0002414491,0.00005445227,0.04767141,0.00009080141,0.2210359,0.0002944557],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9016119,0.01498764,0.009559727,0.06621945,0.003683118,0.0008231336,0.00002405531,0.00002377513,0.003067151],"genre_scores_gemma":[0.9684026,0.009804999,0.0008626743,0.002779841,0.01206266,0.00001429198,0.000005484453,0.00005838128,0.006009116],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5704623,"threshold_uncertainty_score":0.8928959,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2166662937","doi":"10.1056/nejmoa1504030","title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8144,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hotel Dieu Hospital","funders":"National Cancer Institute","keywords":"Nivolumab; Ipilimumab; Medicine; Melanoma; Oncology; Metastatic melanoma; Internal medicine; Dermatology; Immunotherapy; Cancer research; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03693018645658255,"gpt":0.2979048351264862,"spread":0.2609746486699037,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008945439,0.0001523628,0.0005796016,0.0002939526,0.00001890946,0.00000817655,0.00007915643,0.00007842531,0.0002698424],"category_scores_gemma":[0.0002019967,0.00008549287,0.00004315851,0.00029034,0.0001219128,0.00008279349,0.000008885978,0.0002491896,0.000001576891],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001222036,"about_ca_system_score_gemma":0.0004009325,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006296596,"about_ca_topic_score_gemma":0.000233004,"domain_scores_codex":[0.9987099,0.00008286629,0.0005562599,0.000117404,0.0003575801,0.0001760483],"domain_scores_gemma":[0.9990255,0.0001285735,0.0002176983,0.0001360754,0.0001464262,0.0003457482],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2128833,0.0002811393,0.07946607,0.0000578887,0.0004624344,0.001839202,0.006859006,0.000006238468,0.01006321,0.00004113045,0.0270822,0.6609582],"study_design_scores_gemma":[0.7747108,0.02703359,0.07620902,0.001366533,0.000237224,0.005967267,0.001577728,0.0001901703,0.001202161,0.0006771518,0.1105927,0.0002356755],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9774784,0.006373357,0.00007560381,0.01449906,0.0004237994,0.0001765827,9.467872e-7,0.00001228496,0.0009599125],"genre_scores_gemma":[0.9934939,0.002271473,0.0003248501,0.001154035,0.001181677,0.0000010074,0.000003754159,0.00001929427,0.001550009],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6607225,"threshold_uncertainty_score":0.3486298,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2796582438","doi":"10.1056/nejmoa1801005","title":"Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6613,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Merck","keywords":"Pembrolizumab; Chemotherapy; Lung cancer; Medicine; Oncology; Internal medicine; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.01975310630683914,"gpt":0.3120918999598457,"spread":0.2923387936530065,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008693945,0.0001944449,0.0006771708,0.0003336319,0.00003635243,0.000008433301,0.0001533555,0.00006101101,0.001746983],"category_scores_gemma":[0.00006349445,0.000122538,0.0001081531,0.0003689446,0.0001641192,0.00007084013,0.00001055107,0.000355265,0.000003346308],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002584842,"about_ca_system_score_gemma":0.0008082131,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001045888,"about_ca_topic_score_gemma":0.0004100194,"domain_scores_codex":[0.9983981,0.00006111371,0.0006819741,0.0001520248,0.0004266365,0.0002801472],"domain_scores_gemma":[0.998899,0.000102388,0.0003532336,0.0001868767,0.0002122008,0.0002462592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.06940269,0.0004472002,0.04427366,0.0006000112,0.001301999,0.001262157,0.0210356,0.00003802907,0.1460354,0.00002130228,0.09029123,0.6252908],"study_design_scores_gemma":[0.699496,0.009623757,0.06971998,0.004369799,0.001102233,0.003315863,0.001066102,0.001576351,0.01782194,0.0001957315,0.1912626,0.000449596],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9674404,0.01283055,0.0009542705,0.01450415,0.001125049,0.0003094895,0.000001687325,0.00001000398,0.002824413],"genre_scores_gemma":[0.9826633,0.004636517,0.0007557616,0.003805279,0.005948776,0.000003703294,0.000002310034,0.00003242356,0.002151951],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6300933,"threshold_uncertainty_score":0.9991655,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1982488143","doi":"10.1056/nejmoa1501824","title":"Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6228,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Oncology; Internal medicine; PD-L1; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.03835118192736064,"gpt":0.3276515059079407,"spread":0.28930032398058,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004998445,0.0001222081,0.0004452253,0.00008966957,0.0000291927,0.000003384394,0.00009547953,0.00004460709,0.0001251094],"category_scores_gemma":[0.00005411094,0.00005451095,0.0001466183,0.0001111986,0.00008148873,0.00002555725,0.000003750566,0.00008615374,2.893021e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001641186,"about_ca_system_score_gemma":0.0006107431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000722827,"about_ca_topic_score_gemma":0.0001003173,"domain_scores_codex":[0.9990266,0.00002449624,0.0004352391,0.0000751406,0.0002946708,0.0001438678],"domain_scores_gemma":[0.9987973,0.0002286139,0.0003291892,0.000156288,0.0002897909,0.0001988251],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.04456924,0.000462465,0.01486897,0.0001992996,0.00145033,0.00007734124,0.01240694,0.00009923793,0.02467534,0.00001172903,0.08878027,0.8123989],"study_design_scores_gemma":[0.3402529,0.01902882,0.007276616,0.0007016069,0.00219337,0.0006185323,0.001142785,0.0006779204,0.01054188,0.00005561411,0.6173972,0.0001127137],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8672261,0.1024158,0.002716466,0.02359491,0.002055251,0.0007461062,0.000008374918,0.000006610934,0.001230442],"genre_scores_gemma":[0.9724122,0.01565502,0.0004999439,0.0006609772,0.007261263,0.00001297359,0.000003555032,0.00002203095,0.003472044],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8122861,"threshold_uncertainty_score":0.2222892,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2796207838","doi":"10.1016/j.immuni.2018.03.023","title":"The Immune Landscape of Cancer","year":2018,"lang":"en","type":"article","venue":"Immunity","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6191,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital; University of Calgary; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"U.S. National Library of Medicine; National Institute of Environmental Health Sciences; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; National Institute of General Medical Sciences; Cancer Research Institute; National Human Genome Research Institute; U.S. Department of Defense","keywords":"Biology; Immune system; Neuroblastoma RAS viral oncogene homolog; Epigenetics; FOXP3; Cancer research; Immunology; Melanoma; Cancer; Epigenome; KRAS; Gene; Genetics; Gene expression; DNA methylation; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.01786348163548429,"gpt":0.3127203879480663,"spread":0.294856906312582,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002900174,0.00006006459,0.0001218416,0.00002279395,0.0001847429,0.000007659773,0.0001260879,0.00003692111,0.0005869433],"category_scores_gemma":[0.00003462547,0.00003514617,0.00007982621,0.0001650105,0.000321049,0.00002229002,0.00003304644,0.0001062895,0.00001520085],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002275097,"about_ca_system_score_gemma":0.00009171655,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002476296,"about_ca_topic_score_gemma":0.0003972656,"domain_scores_codex":[0.9994993,0.0000365113,0.0001724764,0.00005593798,0.0001097395,0.0001260756],"domain_scores_gemma":[0.9993213,0.0000623096,0.00007218749,0.0003949729,0.0001277454,0.00002149452],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.007752441,0.0002341355,0.06825827,0.00007197761,0.0007885748,0.000002884232,0.001659325,2.168169e-7,0.5414308,0.0003444349,0.007193375,0.3722636],"study_design_scores_gemma":[0.001702899,0.0004132593,0.6392905,0.00009897229,0.00005425591,0.00001027458,0.0004365267,0.00002513861,0.2282339,0.0000673975,0.1295911,0.00007582452],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9721615,0.014394,0.000006662545,0.001163956,0.0003802448,0.0001274666,0.000006080825,0.00002105206,0.01173904],"genre_scores_gemma":[0.9966238,0.001207648,0.00002867828,0.000162803,0.0001296235,0.00001001888,0.000003179818,0.000007719125,0.001826506],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5710322,"threshold_uncertainty_score":0.6426618,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2753432434","doi":"10.1056/nejmoa1709684","title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5392,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Ipilimumab; Nivolumab; Medicine; Melanoma; Oncology; Internal medicine; Overall survival; Metastatic melanoma; Clinical trial; Immunotherapy; Cancer; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.01592681096580529,"gpt":0.2789838467585548,"spread":0.2630570357927495,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000666388,0.0001431115,0.0005620643,0.0001415277,0.00007899645,0.00001812427,0.0001333875,0.00005300195,0.0001015259],"category_scores_gemma":[0.0001707382,0.00008419625,0.00004016894,0.00005114255,0.0002096577,0.0001574883,0.0000182145,0.0002903243,5.196884e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006053952,"about_ca_system_score_gemma":0.0001800242,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004640963,"about_ca_topic_score_gemma":0.0005175115,"domain_scores_codex":[0.9989033,0.00004111908,0.0003892347,0.0001253152,0.0003648155,0.0001762405],"domain_scores_gemma":[0.9989516,0.00009715693,0.0003896134,0.0002594485,0.000103061,0.0001991918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1052024,0.0001933644,0.3421039,0.000115902,0.0004296608,0.001733353,0.001842641,0.000004853407,0.02062057,0.0001678825,0.002617386,0.524968],"study_design_scores_gemma":[0.3370108,0.008938366,0.6307694,0.001402736,0.0001268012,0.001722102,0.0002374611,0.00002372764,0.0004808143,0.0002794832,0.01887976,0.0001285886],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813718,0.002229005,0.00004694268,0.01313378,0.0004736679,0.0001414866,8.948343e-7,0.000005801134,0.002596607],"genre_scores_gemma":[0.9962611,0.001345722,0.0003458069,0.0003381819,0.0009312191,7.30726e-7,0.000001904801,0.00001504956,0.000760324],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5248395,"threshold_uncertainty_score":0.3433423,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2606495925","doi":"10.1186/s13073-017-0424-2","title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","year":2017,"lang":"en","type":"article","venue":"Genome Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3730,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children","funders":"Prostate Cancer Foundation; Foundation Medicine; U.S. Department of Defense","keywords":"Microsatellite instability; Exome sequencing; Germline; Exome; Biology; Somatic cell; Germline mutation; PMS2; Cancer; Computational biology; Cancer research; Medicine; Oncology; Genetics; Gene; Mutation; Microsatellite; Allele","retraction":null,"screen_n_in":null,"score":{"opus":0.03098793945691034,"gpt":0.3341593594147079,"spread":0.3031714199577975,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006013135,0.000131424,0.0006481502,0.0002887377,0.0001913137,0.000006824958,0.0003205962,0.00003544738,0.008092034],"category_scores_gemma":[0.00005462842,0.00007651476,0.0001851945,0.000341817,0.0005616561,0.00003422257,0.00004159011,0.00009302406,0.00000144672],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003755713,"about_ca_system_score_gemma":0.00008359781,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002945069,"about_ca_topic_score_gemma":0.0001537346,"domain_scores_codex":[0.9986826,0.00003332742,0.0005020588,0.0001917841,0.000420395,0.0001699007],"domain_scores_gemma":[0.9983778,0.00007338512,0.0005688439,0.0007127429,0.0002028295,0.00006437182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001051514,0.0001074737,0.6141447,0.0003015221,0.009695997,0.00003547743,0.006275127,0.0001162006,0.3505955,0.0002419883,0.001872253,0.01556223],"study_design_scores_gemma":[0.002281146,0.0003404246,0.9880122,0.0001355881,0.002557254,0.000008643936,0.0007346714,0.00008326238,0.0008811658,0.00008498017,0.004791795,0.00008888008],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9792672,0.008650744,0.00001676262,0.005133185,0.0001237442,0.0002754156,0.00010978,0.000008664066,0.0064145],"genre_scores_gemma":[0.9960729,0.0004136603,0.00003089431,0.0003630205,0.0005188393,0.00002384691,0.00008062401,0.00001262637,0.002483524],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3738675,"threshold_uncertainty_score":0.9928147,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3043703771","doi":"10.1056/nejmoa1910836","title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3708,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Pharmacyclics; Genentech; AstraZeneca; EUSA Pharma; Eisai; National Institute for Health and Care Research; Plexxikon; Array BioPharma; Ipsen; Syndax Pharmaceuticals; Sanofi Genzyme; Pfizer; Incyte; National Cancer Institute; LEO Pharma; Massachusetts Medical Society; Regeneron Pharmaceuticals; Sanofi; GlaxoSmithKline; Amgen; Les Laboratories Pierre Fabre; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Melanoma; Medicine; Oncology; Internal medicine; Metastatic melanoma; Immunotherapy; Cancer research; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.007370799521923161,"gpt":0.2433068734822652,"spread":0.235936073960342,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006051593,0.0001396371,0.0005736695,0.000199022,0.00001741587,0.000005697853,0.00007437507,0.00005428997,0.0003113637],"category_scores_gemma":[0.00006066007,0.00008273435,0.00003922055,0.0002019236,0.00009398336,0.00009310066,0.00001104559,0.0002995899,0.000002874091],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006491112,"about_ca_system_score_gemma":0.0001816432,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000191108,"about_ca_topic_score_gemma":0.0001581241,"domain_scores_codex":[0.9988506,0.00005563536,0.0004006209,0.0001327821,0.0003847387,0.0001755965],"domain_scores_gemma":[0.9992235,0.0001467386,0.0002057322,0.0001496222,0.000103056,0.0001713147],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1413898,0.0002310274,0.5745825,0.0002130801,0.0004969009,0.0007558076,0.003396357,0.0000207894,0.03348949,0.0001748507,0.002858396,0.242391],"study_design_scores_gemma":[0.5209634,0.02121839,0.4249185,0.002078371,0.0001583432,0.001921303,0.001895718,0.00004570258,0.0006937599,0.0001604945,0.02574303,0.0002030414],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895928,0.002143862,0.00002344042,0.005192708,0.0004508911,0.0002067863,9.439315e-7,0.000007275436,0.002381313],"genre_scores_gemma":[0.9964051,0.0008323447,0.0003395254,0.0003441449,0.0005566048,6.325265e-7,0.000003285406,0.0000167441,0.001501611],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3795736,"threshold_uncertainty_score":0.3409214,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2118982164","doi":"10.1056/nejmoa1305133","title":"Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma","year":2013,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3395,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Medicine; Ipilimumab; Rash; Adverse effect; Melanoma; Internal medicine; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Cohort; Cancer; Confidence interval; Surgery; Immunotherapy; Chemotherapy; Phases of clinical research","retraction":null,"screen_n_in":null,"score":{"opus":0.01063699293075173,"gpt":0.2538321199604192,"spread":0.2431951270296674,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006799507,0.0001371432,0.0005102463,0.0002695934,0.00002876782,0.000009656992,0.0000673879,0.00004128444,0.0005252414],"category_scores_gemma":[0.0001667689,0.00007307549,0.00003461498,0.0001989206,0.0001621676,0.0001129638,0.000009831941,0.0002811625,0.000002701523],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005743298,"about_ca_system_score_gemma":0.0002306403,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006451727,"about_ca_topic_score_gemma":0.0001133455,"domain_scores_codex":[0.9987959,0.00008379664,0.0004975513,0.000110217,0.00033229,0.0001802648],"domain_scores_gemma":[0.9991028,0.0002129914,0.0002185108,0.0001265037,0.0001197608,0.0002194156],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1312097,0.0001760914,0.2853508,0.0001677294,0.0004993716,0.002795433,0.003566108,0.000005718526,0.05356995,0.0001060931,0.01205358,0.5104994],"study_design_scores_gemma":[0.1351739,0.00595129,0.7709969,0.001434305,0.000119145,0.01365984,0.0005620619,0.00002186946,0.0007064075,0.0001069508,0.07114492,0.0001223362],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.973516,0.004573677,0.00006300444,0.02011194,0.0001580704,0.0001927079,9.913615e-7,0.000007197382,0.001376421],"genre_scores_gemma":[0.9948958,0.001448771,0.0004160447,0.001321911,0.0009530853,0.000001247034,0.000001450158,0.00001486524,0.000946888],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.510377,"threshold_uncertainty_score":0.5751026,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2120431466","doi":"10.1093/annonc/mdu450","title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3136,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University of British Columbia; University Health Network","funders":"","keywords":"Medicine; Tumor-infiltrating lymphocytes; H&E stain; Breast cancer; Oncology; Medical physics; Cancer; Pathology; Internal medicine; Immunotherapy; Staining","retraction":null,"screen_n_in":null,"score":{"opus":0.08993888139496703,"gpt":0.4238221072094491,"spread":0.3338832258144821,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002569738,0.00007773472,0.0002093827,0.00008968217,0.00005494857,0.000009053675,0.0001468865,0.00006001882,0.0003023208],"category_scores_gemma":[0.0001212023,0.00006055087,0.00006028112,0.0001317501,0.0001143883,0.00010184,0.00001872205,0.00008369033,0.00000132106],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001605096,"about_ca_system_score_gemma":0.0002548231,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001139636,"about_ca_topic_score_gemma":0.001033477,"domain_scores_codex":[0.9987235,0.0002861626,0.0004512737,0.0001427518,0.0002464063,0.000149909],"domain_scores_gemma":[0.9988291,0.0003141205,0.0003565983,0.0001663644,0.0003007472,0.00003312276],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.001088955,0.0002257492,0.03689572,0.00001022561,0.0001077341,3.469869e-7,0.0003293404,0.00003169196,0.02651748,0.0002066614,0.008277467,0.9263086],"study_design_scores_gemma":[0.01335192,0.00284567,0.584641,0.0008675837,0.0001759261,0.0001200614,0.001872641,0.02808954,0.02967475,0.00117029,0.3368494,0.0003412651],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9680704,0.001178881,0.00005945756,0.02284378,0.0005776949,0.0002949898,0.00003698291,0.00001181553,0.006925983],"genre_scores_gemma":[0.9964597,0.00187372,0.0001509087,0.001234276,0.0001398987,0.00005166386,0.00005719033,0.000008259383,0.00002444416],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9259674,"threshold_uncertainty_score":0.3310201,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3171517418","doi":"10.1016/s0140-6736(21)00797-2","title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2927,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Medicine; Gastric adenocarcinoma; Gastro-; Chemotherapy; Nivolumab; Internal medicine; Gastroenterology; Open label; Adenocarcinoma; Gastroesophageal Junction; Oncology; Clinical trial; Cancer; Reflux; Immunotherapy; Disease","retraction":null,"screen_n_in":null,"score":{"opus":0.05805096571869594,"gpt":0.3440784328444417,"spread":0.2860274671257457,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008949838,0.0004805067,0.001479486,0.00008385034,0.0004467197,0.0002011933,0.0004768749,0.0001753961,0.0005185842],"category_scores_gemma":[0.0001576095,0.0003618452,0.0002318726,0.0004487972,0.0002506199,0.0002230779,0.00009902024,0.0003431554,0.00001061682],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002562667,"about_ca_system_score_gemma":0.0004068718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007788491,"about_ca_topic_score_gemma":0.00007074048,"domain_scores_codex":[0.9972915,0.0001417485,0.00069256,0.0007345965,0.0003819254,0.0007576852],"domain_scores_gemma":[0.9978869,0.0003717499,0.0003294455,0.0009854612,0.0002239132,0.0002025375],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9346992,0.0008444701,0.000120239,0.0001473941,0.0008456249,0.00006921827,0.0004528931,0.000009416771,0.01010696,0.00002849906,0.01351179,0.03916432],"study_design_scores_gemma":[0.953059,0.005943913,0.0008547041,0.0001223332,0.0003257326,0.0002043275,0.0001762332,0.001104177,0.008972924,0.0001227674,0.02877633,0.0003376149],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9516562,0.01485495,0.003517448,0.02054486,0.001793948,0.006772846,0.0002311088,0.0001992562,0.0004293675],"genre_scores_gemma":[0.9529112,0.01091273,0.01164558,0.00972098,0.006826744,0.001587116,0.0005393801,0.000253894,0.005602385],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03882671,"threshold_uncertainty_score":0.9998834,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2112121482","doi":"10.1016/s1470-2045(15)70076-8","title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2666,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital; McGill University","funders":"National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Open label; Medicine; Nivolumab; Oncology; Chemotherapy; Internal medicine; Ipilimumab; Randomized controlled trial; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.05803676378711036,"gpt":0.3752254400827541,"spread":0.3171886762956437,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008499426,0.0003240201,0.001726893,0.0000841798,0.00006261166,0.00004530974,0.0003079918,0.0001571798,0.0001433345],"category_scores_gemma":[0.00007141629,0.0001736317,0.00009712103,0.0002495496,0.0002294518,0.0001270311,0.00004423072,0.0001806373,0.00001605522],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007469158,"about_ca_system_score_gemma":0.000615879,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001321132,"about_ca_topic_score_gemma":0.0002011851,"domain_scores_codex":[0.9978956,0.0004020402,0.0005200137,0.0003873867,0.0002708459,0.0005241061],"domain_scores_gemma":[0.9986183,0.0002262894,0.0003233342,0.0005623119,0.0001367393,0.0001330177],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9294716,0.005111363,0.001959539,0.00001318586,0.0008096154,0.00007856489,0.000819838,0.000001611167,0.0002648302,0.000005621738,0.0008322676,0.06063199],"study_design_scores_gemma":[0.905581,0.05465214,0.002115391,0.00007474726,0.0002272193,0.000008712235,0.00009579988,0.00006879399,0.000374184,0.00001079027,0.03658772,0.0002035295],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.982309,0.001048072,0.000006048208,0.003636876,0.0005850302,0.009512851,0.00002825955,0.00004919258,0.002824606],"genre_scores_gemma":[0.9936758,0.0004616587,0.0004728165,0.001460422,0.0004182822,0.002877564,0.00006029124,0.00004996131,0.0005231707],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06042846,"threshold_uncertainty_score":0.7080494,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2635951006","doi":"10.1056/nejmoa1613493","title":"First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer","year":2017,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2575,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Nivolumab; Docetaxel; Medicine; Oncology; Lung cancer; Chemotherapy; Internal medicine; Lung; Cancer; Stage (stratigraphy); Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.03511857503314067,"gpt":0.3199291267709563,"spread":0.2848105517378156,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001248164,0.0005477635,0.001763995,0.0006632486,0.0001035481,0.0000327951,0.0005505381,0.0006175087,0.002988236],"category_scores_gemma":[0.0002759678,0.000326782,0.0002929675,0.0002137751,0.0001930797,0.0001012254,0.00004919909,0.003500634,0.000004040908],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006030151,"about_ca_system_score_gemma":0.001765462,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002858952,"about_ca_topic_score_gemma":0.002713396,"domain_scores_codex":[0.9965493,0.0001106226,0.001404732,0.0003760208,0.0009963247,0.0005629824],"domain_scores_gemma":[0.9967663,0.0003026932,0.001690417,0.0006354681,0.0003065901,0.000298498],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0115277,0.00009888624,0.003196668,0.001568589,0.0004679885,0.01042961,0.0009680431,0.00001036907,0.0002541738,1.263794e-7,0.8869211,0.08455674],"study_design_scores_gemma":[0.1093173,0.003249538,0.002153799,0.01241314,0.0007918507,0.001205432,0.00004824705,0.0001038179,0.00007872848,0.000008937084,0.8703205,0.0003086572],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.04110611,0.04746758,0.0002095333,0.900861,0.007490881,0.0009364841,0.00005517494,0.00001914021,0.001854097],"genre_scores_gemma":[0.02690339,0.1417814,0.0007252145,0.4378339,0.2092569,0.00005199118,0.0002488764,0.0003761722,0.1828222],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.4630271,"threshold_uncertainty_score":0.9999184,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3083986479","doi":"10.1016/s1470-2045(20)30445-9","title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2492,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Cohort; Mesothelioma; Biomarker; Clinical endpoint; Prospective cohort study; Cancer; Progressive disease; Disease; Immunotherapy; Pathology; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.03122114611269687,"gpt":0.3549706413578277,"spread":0.3237494952451308,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003858868,0.0001940642,0.001109758,0.0001183744,0.00006192654,0.00001107944,0.0002973652,0.00005985467,0.00004432455],"category_scores_gemma":[0.0001052071,0.00008896064,0.00005692992,0.00137166,0.0001775989,0.00008706557,0.0000582186,0.0001922041,6.040575e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003845049,"about_ca_system_score_gemma":0.0002772972,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004974001,"about_ca_topic_score_gemma":0.001790371,"domain_scores_codex":[0.9982575,0.0003220151,0.0004229108,0.0002966519,0.0004636568,0.0002372351],"domain_scores_gemma":[0.9983468,0.0002301708,0.0007405409,0.0002887756,0.0003498682,0.00004385175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09481508,0.002597779,0.8913,0.00001721603,0.005599875,0.00001360054,0.002920771,0.0003636715,0.001515355,0.000003960829,0.00003921138,0.0008134344],"study_design_scores_gemma":[0.08969664,0.01016329,0.895515,0.0000436441,0.002315455,0.000001899529,0.0009282193,0.0006623731,0.0005366306,0.000002843388,0.00002375492,0.0001102817],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936353,0.00002425659,0.000014342,0.003369646,0.0000207797,0.002509847,0.0001104518,0.00001585204,0.0002995427],"genre_scores_gemma":[0.9990866,0.000005953128,0.0001958037,0.0003900555,0.00002211765,0.000119022,0.00005353283,0.00002024581,0.0001066475],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007565511,"threshold_uncertainty_score":0.3627709,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2592144107","doi":"10.1016/s1470-2045(17)30074-8","title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2408,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Guideline; Clinical trial; Medicine; Medical physics; Response Evaluation Criteria in Solid Tumors; Immunotherapy; Cancer; Intensive care medicine; Oncology; Internal medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.8623875272759276,"gpt":0.6325735133841923,"spread":0.2298140138917353,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02059164,0.0004207717,0.005353143,0.0001905934,0.0002093897,0.00008925449,0.0006282348,0.0006114243,0.00003331043],"category_scores_gemma":[0.02540172,0.0002423027,0.0009510769,0.0001542576,0.0002202904,0.00005381668,0.0000633879,0.0003454103,0.000005377456],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005018814,"about_ca_system_score_gemma":0.001684447,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009149541,"about_ca_topic_score_gemma":0.0001046674,"domain_scores_codex":[0.9953505,0.00161788,0.001952556,0.000417611,0.0001223027,0.0005391888],"domain_scores_gemma":[0.9759513,0.02070364,0.001631789,0.00121874,0.000450982,0.00004354977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.03372974,0.00006217045,0.000004426758,0.00388851,0.000519349,0.0000119247,0.00006573396,8.306854e-8,0.0001850677,0.00001535452,0.02000875,0.9415089],"study_design_scores_gemma":[0.008306851,0.001282534,0.00004781538,0.008308829,0.001392956,0.0001796262,0.00001631393,0.00004180775,0.000006531438,0.000137892,0.9800229,0.0002559164],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004523365,0.9860235,0.0002421745,0.005322613,0.001600403,0.006041316,0.0005378904,0.00005014982,0.0001366653],"genre_scores_gemma":[0.000002018064,0.9689936,0.02067439,0.002767974,0.003176367,0.002136356,0.0001249131,0.000100487,0.002023891],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9600142,"threshold_uncertainty_score":0.9880818,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2752227448","doi":"10.1056/nejmoa1709030","title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2207,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; Cancer Research UK","keywords":"Ipilimumab; Nivolumab; Medicine; Melanoma; Adjuvant; Adjuvant therapy; Oncology; Internal medicine; Placebo; Immunotherapy; Chemotherapy; Cancer; Cancer research; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.05226193040225233,"gpt":0.3429099879807146,"spread":0.2906480575784622,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001205878,0.0001923283,0.0007476555,0.0003000624,0.0001273738,0.00002473343,0.0003255611,0.0001106871,0.001591968],"category_scores_gemma":[0.0009630507,0.0001121344,0.0001070722,0.0001463202,0.0002287557,0.0001741803,0.00003612124,0.0005341605,0.000004059953],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001979051,"about_ca_system_score_gemma":0.0005900005,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001659461,"about_ca_topic_score_gemma":0.002451594,"domain_scores_codex":[0.9980935,0.00007887619,0.0007449483,0.0001708102,0.0006151259,0.0002966736],"domain_scores_gemma":[0.9981568,0.0002319584,0.0006408591,0.0004934237,0.0001794676,0.0002975321],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3534478,0.0002355113,0.01445743,0.0001150054,0.0006311891,0.005728113,0.002943533,0.000003591568,0.02663212,0.00004175662,0.03425535,0.5615086],"study_design_scores_gemma":[0.6279119,0.01409635,0.1343557,0.002080678,0.0002686164,0.001558377,0.001015742,0.00007219004,0.001891636,0.00005682101,0.2164711,0.0002208841],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9746475,0.003657184,0.00004355324,0.01265136,0.002329313,0.0002269279,0.000003898582,0.00001380158,0.006426458],"genre_scores_gemma":[0.9868551,0.002123629,0.0001812274,0.00031576,0.003499039,0.000001353653,0.000004451913,0.00002324174,0.006996211],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5612877,"threshold_uncertainty_score":0.9993207,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2802206159","doi":"10.1016/s0140-6736(18)30789-x","title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2058,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University Health Network","funders":"Institut National de la Santé et de la Recherche Médicale; National Institutes of Health; Agence Nationale de la Recherche","keywords":"Medicine; Colorectal cancer; Oncology; Internal medicine; Cancer; Nomogram; Confounding; Proportional hazards model; Stage (stratigraphy); Immunotherapy; Clinical endpoint; Prognostic variable; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.07818886738008371,"gpt":0.3702558735660371,"spread":0.2920670061859534,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003823225,0.00004640443,0.0001240055,0.00001275162,0.00008324631,0.000008876285,0.0001695586,0.00001814739,0.00002754179],"category_scores_gemma":[0.0002114975,0.00002026551,0.00003262767,0.0000895792,0.0002739062,0.0000136228,0.00002563484,0.00004746114,3.324239e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002268986,"about_ca_system_score_gemma":0.00005927533,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001943026,"about_ca_topic_score_gemma":0.00008191178,"domain_scores_codex":[0.999535,0.00004736555,0.000160386,0.00007132068,0.0001247533,0.00006117048],"domain_scores_gemma":[0.9989525,0.0004057747,0.000198538,0.0002713762,0.0001663626,0.000005455991],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01623786,0.0003802102,0.4911587,0.0001479918,0.001119509,2.286687e-7,0.007858505,0.000004495068,0.4165193,0.0005187294,0.01304096,0.05301348],"study_design_scores_gemma":[0.003044957,0.0004221367,0.9653237,0.0001050343,0.0001889341,0.000005302296,0.001173537,0.0007350367,0.0202592,0.00008339874,0.0086263,0.00003245648],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862515,0.0004047723,0.00002825014,0.01151407,0.0003105871,0.001227382,0.00004814159,0.000006179022,0.0002091447],"genre_scores_gemma":[0.9991215,0.0001834791,0.00003188543,0.0001728862,0.0002831086,0.0001028469,0.000004534415,0.000004764604,0.00009493513],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.474165,"threshold_uncertainty_score":0.1009219,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2797309423","doi":"10.1056/nejmoa1802357","title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1853,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Genentech; EUSA Pharma; Merck Sharp and Dohme; Eisai; Universiteit van Amsterdam; Incyte; LEO Pharma; Massachusetts Medical Society; Sun Pharma; Regeneron Pharmaceuticals; Syndax Pharmaceuticals; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Adjuvant; Placebo; Stage (stratigraphy); Medicine; Melanoma; Oncology; Internal medicine; Cancer research; Cancer; Biology; Immunotherapy; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.03049556086374712,"gpt":0.3167479901321354,"spread":0.2862524292683883,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001095531,0.0001682198,0.0005864704,0.0003982932,0.00004267339,0.000007210888,0.0001496808,0.00009515366,0.001883331],"category_scores_gemma":[0.0004016693,0.0001068676,0.00008446343,0.0003789655,0.0002321747,0.00008604043,0.00001823163,0.0004267736,0.000008039587],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001816728,"about_ca_system_score_gemma":0.0004298281,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006565588,"about_ca_topic_score_gemma":0.000802197,"domain_scores_codex":[0.9982115,0.0001021621,0.0006951235,0.0001472563,0.0005665971,0.0002773669],"domain_scores_gemma":[0.9987265,0.0002357018,0.0003123904,0.0002198509,0.000231276,0.0002742114],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.558945,0.0001899679,0.008292303,0.00007795201,0.0005687808,0.001941987,0.005846172,0.000003567331,0.06385048,0.00009194964,0.04088935,0.3193025],"study_design_scores_gemma":[0.6657964,0.01912724,0.04556589,0.001262939,0.0002053931,0.00170449,0.0009228694,0.00007757299,0.004483543,0.00006545214,0.260605,0.0001831805],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9776355,0.003463669,0.0001048368,0.007057996,0.001920796,0.0002088438,0.000002058362,0.00001512198,0.009591165],"genre_scores_gemma":[0.9900509,0.000766306,0.0001827511,0.0005308668,0.006034088,0.000001117231,0.000005242668,0.00002013312,0.002408599],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3191193,"threshold_uncertainty_score":0.9990291,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3109853980","doi":"10.1016/s0140-6736(20)32531-9","title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1800,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Gemcitabine; Internal medicine; Pembrolizumab; Triple-negative breast cancer; Breast cancer; Oncology; Chemotherapy; Docetaxel; Metastatic breast cancer; Placebo; Taxane; Cancer; Pathology; Cisplatin; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.1378372333894381,"gpt":0.4138224453152746,"spread":0.2759852119258366,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002386028,0.0008400741,0.003758484,0.0001161856,0.0003361331,0.0001834749,0.0007585448,0.0002955937,0.002016246],"category_scores_gemma":[0.0005664412,0.0004903047,0.001148931,0.0007175306,0.0004424783,0.0001855835,0.00005452823,0.0008269573,0.00003479399],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007191764,"about_ca_system_score_gemma":0.002545959,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004677463,"about_ca_topic_score_gemma":0.0003363751,"domain_scores_codex":[0.9946421,0.0006980759,0.001822387,0.001026053,0.0007048402,0.001106564],"domain_scores_gemma":[0.9950906,0.002272247,0.000878583,0.0009265589,0.000360761,0.0004712307],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9188595,0.0008101193,0.000008858286,0.0002578813,0.005583826,0.00003013298,0.002832423,0.0001012691,0.0002703697,0.00001662326,0.02589051,0.04533847],"study_design_scores_gemma":[0.9551997,0.01092236,0.0000175688,0.000313245,0.001771073,0.00005150605,0.0004428684,0.0125458,0.0008277407,0.00001853617,0.01729247,0.0005971879],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8241286,0.006039119,0.003428156,0.0861468,0.003965862,0.07316691,0.001234799,0.0006683425,0.001221439],"genre_scores_gemma":[0.887015,0.02717386,0.002205822,0.03707374,0.01784672,0.02106357,0.0005872868,0.0006253496,0.006408625],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06288645,"threshold_uncertainty_score":0.9997548,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2945057866","doi":"10.1038/s41568-019-0144-6","title":"Tertiary lymphoid structures in the era of cancer immunotherapy","year":2019,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1784,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Labex Immuno-Oncology; Sorbonne Université; Institut National de la Santé et de la Recherche Médicale; Institute of Cancer Research; Institut National Du Cancer; Association pour la Recherche sur le Cancer","keywords":"Immunotherapy; Cancer immunotherapy; Medicine; Cancer; Immunology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03471973675741632,"gpt":0.4036705072742845,"spread":0.3689507705168682,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009044133,0.0008356902,0.00417875,0.0002411691,0.00004278752,0.00003043652,0.0008381976,0.001252824,0.0009976384],"category_scores_gemma":[0.00005293757,0.0004223092,0.001857109,0.001191544,0.0001586971,0.00007832537,0.00004762138,0.002656463,0.00001308134],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007426417,"about_ca_system_score_gemma":0.001653668,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009847354,"about_ca_topic_score_gemma":0.0002978141,"domain_scores_codex":[0.9961128,0.0005126209,0.001594114,0.000678531,0.0006211748,0.0004807311],"domain_scores_gemma":[0.9970424,0.0002386863,0.001200266,0.001352749,0.0001089787,0.00005699163],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001881904,0.00005716425,0.0002477767,0.04297477,0.0006664314,0.000009435699,0.0001640187,1.972487e-7,0.00002913588,0.00002511914,0.01018825,0.9454495],"study_design_scores_gemma":[0.001194503,0.00006531036,0.0006496858,0.07433224,0.001392419,0.00009647336,0.00001132651,3.710524e-7,0.00001570121,0.0000114427,0.9218257,0.0004048305],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003341615,0.9925163,9.122049e-7,0.0005676636,0.001626533,0.004711389,0.0001909879,0.00003152852,0.000321243],"genre_scores_gemma":[0.00003131707,0.9917673,0.00006801942,0.005457233,0.0008006311,0.001267386,0.0001028891,0.0001578995,0.0003473025],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9450447,"threshold_uncertainty_score":0.9999156,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1990675339","doi":"10.1016/s0140-6736(14)60958-2","title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1761,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Ipilimumab; Internal medicine; Clinical endpoint; Adverse effect; Refractory (planetary science); Cohort; Clinical trial; Melanoma; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Surgery; Phases of clinical research; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.03062678598511109,"gpt":0.3242064810358412,"spread":0.2935796950507301,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006192448,0.0002622988,0.001406985,0.00009100085,0.00005576897,0.000016866,0.0001905708,0.00008784483,0.0001505878],"category_scores_gemma":[0.00004702157,0.0001424546,0.0001872584,0.0002330869,0.0001668667,0.00005466611,0.00001432598,0.0001784957,0.000008606577],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001899516,"about_ca_system_score_gemma":0.0001454284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003805471,"about_ca_topic_score_gemma":0.0001265799,"domain_scores_codex":[0.9982716,0.0002129461,0.0005209076,0.0003019026,0.000304299,0.0003883187],"domain_scores_gemma":[0.9986724,0.0002323107,0.0002789467,0.0006925592,0.00004775856,0.0000760688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8761943,0.001853549,0.02052151,0.00005384381,0.0004718666,0.000006689193,0.0007566937,0.000006860146,0.01661519,0.00001694194,0.000350249,0.08315232],"study_design_scores_gemma":[0.9253135,0.0120535,0.02001471,0.0001847429,0.0002885875,0.00001478444,0.0001579328,0.0002438907,0.007890371,0.00001194588,0.03362464,0.0002014115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932293,0.001193843,0.00005817788,0.0006052008,0.0002048058,0.002667353,0.0000209575,0.00006452423,0.001955864],"genre_scores_gemma":[0.9979113,0.0004900259,0.0002926097,0.0001493525,0.0004923126,0.0003931238,0.00006188032,0.00003106901,0.0001783422],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0829509,"threshold_uncertainty_score":0.580913,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2910245285","doi":"10.1200/jco.18.00149","title":"Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1716,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Internal medicine; Hazard ratio; Oncology; Tolerability; Clinical endpoint; Chemotherapy regimen; Surgery; Cancer; Confidence interval; Randomized controlled trial; Immunotherapy; Adverse effect","retraction":null,"screen_n_in":null,"score":{"opus":0.06235330001325926,"gpt":0.4207660967554982,"spread":0.3584127967422389,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001234685,0.0002086523,0.002218437,0.0003424612,0.0000234059,0.000004754134,0.0001788529,0.000276954,0.001046397],"category_scores_gemma":[0.0001684701,0.0001237587,0.0008853101,0.0005441471,0.0001971503,0.00008308437,0.00001249447,0.0003822944,7.94325e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002417742,"about_ca_system_score_gemma":0.003000902,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007450489,"about_ca_topic_score_gemma":0.0001920828,"domain_scores_codex":[0.9965624,0.0001173432,0.00241095,0.0002676988,0.0003888527,0.0002528068],"domain_scores_gemma":[0.994031,0.0007432016,0.003880802,0.0002970159,0.0008973403,0.0001506003],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7264834,0.001247091,0.2294607,0.0003552974,0.006082542,0.00005096097,0.0001418393,0.001272324,0.01565949,0.000001282562,0.0004395106,0.01880558],"study_design_scores_gemma":[0.237349,0.08075658,0.6128643,0.0008317154,0.01146565,0.00004459859,0.000318929,0.009887537,0.03912994,0.000004630272,0.006972005,0.000375071],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961542,0.000264054,0.0007487654,0.001041489,0.0006232134,0.0009131513,0.00003169732,0.000007285986,0.0002160804],"genre_scores_gemma":[0.9933583,0.0002205901,0.004803628,0.0009128539,0.0001941218,0.00002094371,0.00002513931,0.00003254385,0.000431885],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4891344,"threshold_uncertainty_score":0.9998668,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2946386783","doi":"10.1016/s1470-2045(19)30167-6","title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1681,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"William Osler Health System","funders":"F. Hoffmann-La Roche","keywords":"Carboplatin; Medicine; Paclitaxel; Atezolizumab; Chemotherapy; Oncology; Nab-paclitaxel; Open label; Internal medicine; Lung cancer; Cisplatin; Cancer; Randomized controlled trial; Nivolumab; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.04848363890646765,"gpt":0.3745263839184664,"spread":0.3260427450119987,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008126488,0.0005305943,0.002057799,0.000142406,0.0001496843,0.00006186465,0.0004141528,0.0001651716,0.0003009691],"category_scores_gemma":[0.00002088924,0.0003147473,0.0001289025,0.0004013135,0.0001689769,0.0001125532,0.00003286235,0.0002667205,0.000009096651],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001669292,"about_ca_system_score_gemma":0.001256861,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00464751,"about_ca_topic_score_gemma":0.006687745,"domain_scores_codex":[0.9974245,0.0002184191,0.000713366,0.0006279192,0.0002871266,0.0007285972],"domain_scores_gemma":[0.9975975,0.0008134393,0.0006043657,0.0006867169,0.0001685544,0.0001294434],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9677392,0.006894242,0.001005181,0.0003043417,0.001308195,0.00006326105,0.00610342,0.0003058375,0.005830334,0.000008782099,0.0007205427,0.009716677],"study_design_scores_gemma":[0.926024,0.03383809,0.0005579339,0.0002751585,0.0006166384,0.0000562704,0.000587897,0.02512565,0.004592743,0.00001705764,0.007892759,0.000415774],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9676853,0.001136664,0.0005747847,0.007206224,0.0003377473,0.02202023,0.00008264299,0.00004875455,0.0009075878],"genre_scores_gemma":[0.9867935,0.001625546,0.0022427,0.002967075,0.0002800841,0.004031883,0.0001960679,0.0001121823,0.001750931],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04171515,"threshold_uncertainty_score":0.9999304,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2117878645","doi":"10.1158/1078-0432.ccr-09-0265","title":"Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1648,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; York University; Chemotherapy Foundation; Breast Cancer Research Foundation; U.S. Department of Defense","keywords":"Abscopal effect; Radiation therapy; Medicine; CD8; Cancer research; Antibody; Immunotherapy; Growth inhibition; Nasopharyngeal carcinoma; Carcinoma; Dose fractionation; Regimen; Immune system; Oncology; Internal medicine; Immunology; Cell growth; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1219258312480413,"gpt":0.4906271966923983,"spread":0.3687013654443569,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004085281,0.0003704131,0.001027217,0.0003782412,0.000330253,0.000145827,0.0004523801,0.0004528555,0.001149314],"category_scores_gemma":[0.00055157,0.0002637548,0.000263881,0.001013991,0.0009102729,0.000313486,0.00003994117,0.001774427,0.00004717086],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004257463,"about_ca_system_score_gemma":0.0009944,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001643023,"about_ca_topic_score_gemma":0.00007898942,"domain_scores_codex":[0.9947349,0.001124049,0.0009482299,0.0008820029,0.001409165,0.0009016391],"domain_scores_gemma":[0.9961854,0.001577738,0.0002269997,0.000871111,0.0006422939,0.0004965005],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0931854,0.001893324,0.02667197,0.00007414523,0.000557245,0.0002080646,0.000205833,0.000003811416,0.7958717,0.000007674221,0.001730254,0.07959054],"study_design_scores_gemma":[0.03568558,0.05304797,0.7715359,0.0006714952,0.0001138336,0.00006426429,0.0001284587,0.0003712729,0.1254942,0.00005284534,0.01221507,0.0006191226],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868281,0.00272725,0.00002518188,0.0075472,0.0004825426,0.001532249,0.00003561607,0.0001937503,0.0006281238],"genre_scores_gemma":[0.9926823,0.002829348,0.0002158802,0.00234718,0.0008515308,0.00008144534,0.0002211486,0.00007443286,0.0006966804],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7448639,"threshold_uncertainty_score":0.9999815,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139591061","doi":"10.1158/0008-5472.can-11-1620","title":"Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1645,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; U.S. Public Health Service","keywords":"Immune system; Cancer; Cancer research; Receptor; Antibody; Immunology; Ipilimumab; Biology; Inhibitory postsynaptic potential; CD8; Blockade; Cancer cell; Immune tolerance; Knockout mouse; Immunotherapy; Neuroscience; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.05320576067752921,"gpt":0.3317385669488215,"spread":0.2785328062712923,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001020568,0.0001965667,0.0003184398,0.0002981451,0.0002067191,0.00004644561,0.0001699026,0.0001284489,0.0009115214],"category_scores_gemma":[0.00006944034,0.0001682173,0.00009830853,0.0005510032,0.0003852153,0.00009227807,0.0001629047,0.0004701394,0.00007827401],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002548077,"about_ca_system_score_gemma":0.0003543666,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00157207,"about_ca_topic_score_gemma":0.00005588025,"domain_scores_codex":[0.9978055,0.0001313385,0.0003670111,0.0004856489,0.0005900924,0.0006203992],"domain_scores_gemma":[0.9987682,0.00003795293,0.00005471187,0.0005038261,0.0003521006,0.0002832433],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.008841645,0.0001681639,0.0003424487,0.0002201522,0.00009766652,0.00007786239,0.0006832185,9.30288e-7,0.9560429,0.0001584532,0.001830956,0.03153555],"study_design_scores_gemma":[0.00465548,0.003272388,0.1212803,0.000930413,0.00009991222,0.00005570636,0.0004875717,0.00008472286,0.8317112,0.0004161405,0.03654048,0.000465609],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816204,0.009819899,0.0001153232,0.001041398,0.000321171,0.0008873799,0.00001263935,0.00007015327,0.00611162],"genre_scores_gemma":[0.9909682,0.0009364513,0.0004917078,0.0002289374,0.0002427101,0.0002105236,0.00001244058,0.0000565451,0.006852482],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1243317,"threshold_uncertainty_score":0.998052,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3128131226","doi":"10.1038/s41571-021-00473-5","title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","year":2021,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1560,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Biomarker; Concordance; Biomarker discovery; Oncology; Companion diagnostic; Immune checkpoint; Clinical trial; PD-L1; Cancer; Disease; Internal medicine; Immunotherapy; Bioinformatics; Biology; Proteomics","retraction":null,"screen_n_in":null,"score":{"opus":0.1525086424784524,"gpt":0.5349054464247085,"spread":0.3823968039462561,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.01688328,0.0009095914,0.01373718,0.0005224074,0.00005970756,0.00001672436,0.0006276474,0.005632502,0.001535454],"category_scores_gemma":[0.02243347,0.0006032166,0.008643927,0.001980483,0.0004422641,0.00004207736,0.0003991726,0.004371546,0.0005640332],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008330241,"about_ca_system_score_gemma":0.005869745,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002823496,"about_ca_topic_score_gemma":0.00001563997,"domain_scores_codex":[0.9825356,0.006602943,0.008367545,0.001332429,0.0005515879,0.0006098984],"domain_scores_gemma":[0.9880369,0.005672629,0.003345355,0.001943464,0.0004341092,0.0005674824],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.006716549,0.00079532,0.000006101302,0.01255589,0.00125532,0.0003510673,0.00002621952,2.750898e-9,0.0001259506,0.00001230668,0.03256044,0.9455948],"study_design_scores_gemma":[0.002159646,0.00350645,0.0001383518,0.06610335,0.003216933,0.0007034185,0.00001306269,9.893824e-8,0.00001781029,0.000005524714,0.9236523,0.0004830764],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00006484905,0.9856509,0.000004238408,0.002961357,0.003829922,0.004520376,0.00004776563,0.00004585047,0.002874737],"genre_scores_gemma":[0.0000110015,0.9892741,0.001752813,0.004350343,0.000915569,0.0003779761,0.0001742754,0.0001215428,0.003022358],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9451118,"threshold_uncertainty_score":0.9997661,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2789315292","doi":"10.1016/j.jacc.2018.02.037","title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1542,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Ted Rogers Centre for Heart Research; Toronto General Hospital; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; Kohlberg Foundation; Sarnoff Cardiovascular Research Foundation; Canadian Institutes of Health Research; Harvard University Center for AIDS Research; American Heart Association","keywords":"Medicine; Myocarditis; Immune system; Immune checkpoint; Immunology; Internal medicine; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.006600490092082035,"gpt":0.2368405581345571,"spread":0.2302400680424751,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003441525,0.0001128438,0.0008196366,0.0001730647,0.00003141366,0.000001616368,0.0001503357,0.0000400711,0.00001073433],"category_scores_gemma":[0.000069469,0.00006220328,0.0003565302,0.0005858337,0.0009168215,0.00003525601,0.00003214359,0.0001772421,9.090372e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001598751,"about_ca_system_score_gemma":0.0001916824,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007841348,"about_ca_topic_score_gemma":0.000009190946,"domain_scores_codex":[0.99876,0.0001740227,0.0005648001,0.00009433944,0.0002391495,0.0001677125],"domain_scores_gemma":[0.9985323,0.00004731663,0.0007935595,0.0002455753,0.000336409,0.00004482265],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01711559,0.00008286013,0.9587404,0.00001216146,0.0009947076,0.0001040448,0.00006508224,0.00001133502,0.01570697,0.000003648441,0.003327364,0.003835804],"study_design_scores_gemma":[0.004828549,0.007024613,0.9679315,0.0001672982,0.0001322913,0.0006589067,0.0002395764,0.000001900238,0.01350993,0.000008498295,0.005423635,0.00007328722],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972519,0.0001865364,0.00001080619,0.0008598893,0.0002996976,0.0001835186,0.00002139887,0.000003149145,0.001183148],"genre_scores_gemma":[0.999149,0.0001020902,0.000141398,0.0002020562,0.0003139001,0.000002046357,7.886683e-7,0.00001355883,0.0000751635],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01228704,"threshold_uncertainty_score":0.3378067,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2896600825","doi":"10.1016/s1470-2045(18)30700-9","title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1409,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Internal medicine; Oncology; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.059457284228469,"gpt":0.3855917897477813,"spread":0.3261345055193123,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001466869,0.0004203306,0.002274485,0.0002232364,0.0001463984,0.00001766271,0.0005287401,0.0003273101,0.0011513],"category_scores_gemma":[0.0006880736,0.0002740658,0.0003541765,0.0005495101,0.000811893,0.0001312383,0.0001347581,0.0004628996,0.00009868885],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008381379,"about_ca_system_score_gemma":0.0008374284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000670462,"about_ca_topic_score_gemma":0.003888741,"domain_scores_codex":[0.9964208,0.0005532781,0.001154732,0.0005568044,0.0004357318,0.0008786446],"domain_scores_gemma":[0.9968739,0.001162812,0.0005888959,0.00104268,0.0001895754,0.0001421445],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9536278,0.001443665,0.0004076472,0.00008974916,0.0007904752,0.0001135082,0.001876405,0.000004915042,0.008165564,0.00003213917,0.00157358,0.03187456],"study_design_scores_gemma":[0.9513123,0.01552613,0.002623274,0.0001233043,0.0004007438,0.00005105363,0.001137759,0.0005143405,0.004532529,0.00003452764,0.02342135,0.0003226896],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870612,0.0007673303,0.0000448051,0.00282389,0.002373919,0.003143369,0.00007041116,0.0001149987,0.003600048],"genre_scores_gemma":[0.9939461,0.0009182284,0.001097163,0.0008566226,0.001084869,0.0002585417,0.00004600564,0.00006444114,0.001728002],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03155187,"threshold_uncertainty_score":0.9999712,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1859257957","doi":"10.1002/path.4287","title":"Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours","year":2013,"lang":"en","type":"review","venue":"The Journal of Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1347,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Labex Immuno-Oncology; Cancer Research Institute; Qatar National Research Fund; Institut National de la Santé et de la Recherche Médicale; Institut National Du Cancer; Assistance publique-Hôpitaux de Paris; Fonds National de la Recherche Luxembourg; European Commission; Pathological Society of Great Britain and Ireland; National Center for Advancing Translational Sciences; Japan Association for Chemical Innovation; Society for Immunotherapy of Cancer","keywords":"Medicine; Oncology; Colorectal cancer; Cancer staging; Cancer; Stage (stratigraphy); Internal medicine; Immune system; TNM staging system; Neoplasm staging; Immunology; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.07554092438918289,"gpt":0.3444991782666527,"spread":0.2689582538774699,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004322637,0.0001839607,0.000941911,0.0001352036,0.00006266793,0.000006688682,0.0008620316,0.0001695747,0.00006792713],"category_scores_gemma":[0.0002039919,0.00005531672,0.000525918,0.0004384228,0.0006121949,0.00003527933,0.00005088381,0.0008212538,0.00000285155],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001046449,"about_ca_system_score_gemma":0.0004187659,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006103554,"about_ca_topic_score_gemma":0.00001196096,"domain_scores_codex":[0.9963945,0.001822166,0.001181439,0.00009750664,0.0003521921,0.000152203],"domain_scores_gemma":[0.9964116,0.0002793111,0.002334121,0.0007600563,0.0002017585,0.00001316121],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006148531,0.0002117684,0.00007709629,0.001654769,0.0003544171,0.00001688874,0.003088634,0.000001917855,0.009541974,0.0004274011,0.006111385,0.9778989],"study_design_scores_gemma":[0.00141667,0.001429609,0.0428139,0.006669599,0.004022362,0.01858344,0.003621716,0.00000423615,0.0006523213,0.0004944717,0.9201011,0.0001905805],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01583661,0.9720396,0.00002659238,0.0101499,0.0009481442,0.0008334242,0.00000803317,0.000001741924,0.000155973],"genre_scores_gemma":[0.01797917,0.9811202,0.00002467899,0.0001625905,0.0005598852,0.00001721672,0.000004104197,0.00001701584,0.0001151787],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9777083,"threshold_uncertainty_score":0.3567985,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3049052172","doi":"10.1126/science.abc3421","title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","year":2020,"lang":"en","type":"article","venue":"Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1341,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Alberta Children's Hospital; University of Calgary","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Alberta Innovates; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Inosine; Immunotherapy; Microbiome; Computational biology; Chemistry; Biology; Immunology; Immune system; Bioinformatics; Biochemistry; Adenosine","retraction":null,"screen_n_in":null,"score":{"opus":0.01902200474979086,"gpt":0.2797730999589675,"spread":0.2607510952091767,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006248602,0.000138553,0.0001946778,0.0001666072,0.0001553099,0.00006500568,0.0002742753,0.00004020422,0.0002225117],"category_scores_gemma":[0.0001824595,0.0001125622,0.00008271273,0.001581462,0.0004532215,0.0001430039,0.00007792008,0.00009867809,0.0001365552],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001515862,"about_ca_system_score_gemma":0.0003765428,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002419438,"about_ca_topic_score_gemma":0.000001288914,"domain_scores_codex":[0.9986539,0.00003062423,0.000239536,0.0004208832,0.0003229011,0.0003321162],"domain_scores_gemma":[0.9992361,0.00002765443,0.00005162389,0.0003064863,0.000121064,0.000257053],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.008439165,0.00003980843,0.0002741898,0.00001130039,0.00001350695,0.00001015058,0.002022002,0.000003182723,0.9791994,0.000001771348,0.0006145341,0.009371],"study_design_scores_gemma":[0.001661871,0.0008508257,0.04234922,0.00006563951,0.000004941142,0.00002370553,0.000185693,0.00008965309,0.9055729,0.000005261022,0.04903928,0.0001510169],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9661853,0.000599126,0.0002501621,0.03213581,0.0002405748,0.0003823932,0.000007652101,0.00009304225,0.000105951],"genre_scores_gemma":[0.985183,0.0000460362,0.002631455,0.01173605,0.0001171478,0.000008068254,0.000001828651,0.00001643754,0.0002599914],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07362649,"threshold_uncertainty_score":0.4590155,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4226329559","doi":"10.3390/curroncol29050247","title":"Immune Checkpoint Inhibitors in Cancer Therapy","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1280,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false},"ca_institutions":"","funders":"","keywords":"Nivolumab; Durvalumab; Medicine; Ipilimumab; Avelumab; Pembrolizumab; Atezolizumab; Immunotherapy; CTLA-4; Immune checkpoint; Cancer; Cancer immunotherapy; Lung cancer; Oncology; Immunology; Immune system; Cancer research; Internal medicine; T cell","retraction":null,"screen_n_in":null,"score":{"opus":0.2411030219700868,"gpt":0.483593654542637,"spread":0.2424906325725502,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006497913,0.0004409261,0.002346951,0.0004651385,0.00006377135,0.000009111559,0.0002557948,0.0003495729,0.006004217],"category_scores_gemma":[0.00003616733,0.0003394297,0.00101143,0.0007412038,0.0001366077,0.00002944563,0.0001202404,0.001355979,0.00003172931],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002970228,"about_ca_system_score_gemma":0.00232687,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002482271,"about_ca_topic_score_gemma":0.00006511252,"domain_scores_codex":[0.9972448,0.0003463106,0.001203693,0.0005227057,0.0002529308,0.0004295105],"domain_scores_gemma":[0.9987418,0.0001661749,0.0005471286,0.0004297874,0.0000279951,0.00008713399],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003813348,0.0007268069,0.00006287485,0.004390588,0.0002388104,0.00005190719,0.0001774956,5.623196e-8,0.000008230472,0.000004174216,0.002584379,0.9913734],"study_design_scores_gemma":[0.002812099,0.000678694,0.00008028169,0.006042549,0.0002493752,0.0001046321,0.00004433147,7.856754e-7,0.000006358304,0.000005422437,0.9896659,0.0003095811],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001205783,0.9898076,4.61742e-7,0.0002625862,0.006529124,0.001697807,0.00004033564,0.00004791729,0.001493575],"genre_scores_gemma":[0.000006355182,0.9965318,0.000008583744,0.0001048421,0.0007212281,0.001888094,0.0002644949,0.00007152409,0.000403019],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9910638,"threshold_uncertainty_score":0.9999058,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2557730509","doi":"10.1016/j.jtho.2016.11.2228","title":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1254,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Celgene; AstraZeneca","keywords":"Immunohistochemistry; Medicine; Staining; Pathology; Companion diagnostic; Lung cancer; Cancer; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.04763398284113613,"gpt":0.4766245741671307,"spread":0.4289905913259946,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001990494,0.0002164476,0.0009089664,0.0001160351,0.00009990606,0.00001195515,0.0004378411,0.0002972332,0.0001758989],"category_scores_gemma":[0.0007369761,0.0001171749,0.0005673121,0.0001910275,0.0002837927,0.00009176498,0.0000745008,0.0004326063,0.000001056993],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001257573,"about_ca_system_score_gemma":0.001769234,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003071135,"about_ca_topic_score_gemma":0.00004828275,"domain_scores_codex":[0.9973462,0.0002710322,0.001424735,0.0002544046,0.0003963424,0.0003073234],"domain_scores_gemma":[0.9957907,0.0008912259,0.00218213,0.0004969638,0.0005418003,0.00009718961],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.08170766,0.0008002641,0.001628458,0.0001162794,0.0008706921,0.00002205078,0.0007174523,0.000004053292,0.702617,0.000003878523,0.03067177,0.1808405],"study_design_scores_gemma":[0.02984146,0.004093209,0.009651,0.00270539,0.001697661,0.0004039729,0.0008791973,0.0004388066,0.7456428,0.0001445539,0.2041421,0.0003598219],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9754738,0.005153006,0.002416037,0.01213288,0.002042829,0.000794007,0.0004833092,0.00001779693,0.001486329],"genre_scores_gemma":[0.9943413,0.0006373579,0.002444823,0.0003352006,0.0007932545,0.00003825116,0.00001256978,0.00002881627,0.001368468],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1804806,"threshold_uncertainty_score":0.4778253,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2747107882","doi":"10.1016/s0140-6736(17)31601-x","title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1239,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Ipilimumab; Medicine; Open label; Oncology; Open label study; Internal medicine; Clinical trial; Adverse effect; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.133872475199361,"gpt":0.4107823894404024,"spread":0.2769099142410414,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001117227,0.0002362768,0.0009617754,0.00003766601,0.0003900026,0.0001042479,0.001031315,0.00006788057,0.00005018215],"category_scores_gemma":[0.0007838189,0.0001557057,0.0001377322,0.00005643666,0.0001800511,0.0001772572,0.0001848235,0.0001768529,0.000006726032],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008482594,"about_ca_system_score_gemma":0.0001569523,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005549492,"about_ca_topic_score_gemma":0.000384339,"domain_scores_codex":[0.9982678,0.0001239425,0.0005109443,0.0003716107,0.0003130775,0.0004125983],"domain_scores_gemma":[0.9970744,0.0005478613,0.0005188358,0.001633641,0.0001491237,0.00007618272],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.962203,0.002195244,0.0002884663,0.00007554208,0.0006598479,0.00001949652,0.0008875672,0.000003471451,0.006797587,0.00004778746,0.004157762,0.02266423],"study_design_scores_gemma":[0.9711376,0.005638995,0.008268356,0.0001301062,0.0003917189,0.000006010965,0.0004427594,0.0004626653,0.002311778,0.00004819667,0.01095573,0.0002060334],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863697,0.0004635621,0.00003978979,0.002587182,0.0009580092,0.004183849,0.0003833238,0.00003481789,0.004979709],"genre_scores_gemma":[0.9966482,0.0002268201,0.0005381962,0.0001698124,0.0005573681,0.0001943222,0.00005732565,0.00003140136,0.001576538],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0224582,"threshold_uncertainty_score":0.6349494,"prediction_status":"machine_predicted_unvalidated"},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2095826876","doi":"10.1016/s1470-2045(09)70334-1","title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1187,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Ipilimumab; Adverse effect; Clinical endpoint; Internal medicine; Melanoma; Clinical trial; Intention-to-treat analysis; Phases of clinical research; Randomized controlled trial; Gastroenterology; Surgery; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03300815461349548,"gpt":0.3521155906350885,"spread":0.319107436021593,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056647,0.0002538181,0.0008265198,0.0001424006,0.00009655743,0.0000169206,0.0002054138,0.0001052391,0.00009288111],"category_scores_gemma":[0.00001877505,0.0001480776,0.00008670743,0.0004532576,0.00008662756,0.00008944559,0.00001433771,0.0003059412,0.000008896756],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003258603,"about_ca_system_score_gemma":0.0001274515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009706428,"about_ca_topic_score_gemma":0.0002377467,"domain_scores_codex":[0.9982696,0.000236804,0.0004245672,0.0003465868,0.0002376412,0.0004848287],"domain_scores_gemma":[0.998999,0.0001501647,0.0001993442,0.0004992302,0.00008243728,0.00006984211],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8571087,0.005183978,0.03736975,0.00001116338,0.0003133106,0.00006805392,0.0032286,0.00003542776,0.0008870782,0.000005891516,0.00009378365,0.09569432],"study_design_scores_gemma":[0.8226077,0.01096222,0.1632927,0.00006380224,0.0001471496,0.000009921631,0.0005293525,0.00009203379,0.0003087837,0.00001086462,0.001798552,0.0001769449],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990895,0.0005197068,0.00002110932,0.001699416,0.000135964,0.004800705,0.000006296145,0.00008791396,0.001833865],"genre_scores_gemma":[0.9975108,0.0001477412,0.0002554978,0.001540789,0.0001452675,0.0001880558,0.00003379962,0.00002572873,0.0001523488],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1259229,"threshold_uncertainty_score":0.6038431,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2947775394","doi":"10.1200/jco.19.00934","title":"Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1185,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Pembrolizumab; Overall survival; Lung cancer; Safety profile; Phases of clinical research; Survival rate; Cancer; Lung","retraction":null,"screen_n_in":null,"score":{"opus":0.04314214802703654,"gpt":0.41046673368768,"spread":0.3673245856606435,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001303204,0.0002287676,0.001318609,0.00005239204,0.00006518605,0.00001643309,0.0002498374,0.0002137691,0.0001462808],"category_scores_gemma":[0.0003299956,0.0001095347,0.0002923182,0.000132795,0.0001184828,0.0001064767,0.00002880304,0.0006702083,0.000003986321],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002160834,"about_ca_system_score_gemma":0.001227233,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005998812,"about_ca_topic_score_gemma":0.0006740182,"domain_scores_codex":[0.9970221,0.0003070209,0.001606067,0.0003336384,0.0004377814,0.0002933878],"domain_scores_gemma":[0.9940013,0.002860307,0.001861461,0.0003607323,0.0007187934,0.0001973758],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5069,0.008801681,0.4618699,0.00001808505,0.001502027,0.00006349218,0.0003464732,0.00005990962,0.0001294848,5.651299e-7,0.002462503,0.01784584],"study_design_scores_gemma":[0.3197525,0.08178364,0.583197,0.0001826613,0.000922045,0.00000507761,0.0003736066,0.0001238783,0.00004051127,0.000002835066,0.0134721,0.0001441624],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949187,0.0002102493,0.00002952657,0.00130581,0.0009149317,0.001851518,0.0001532204,0.000009561762,0.000606453],"genre_scores_gemma":[0.9962134,0.0003029879,0.0005825346,0.001175649,0.0006551133,0.00002475715,0.00004631916,0.00003721593,0.0009619929],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1871476,"threshold_uncertainty_score":0.4466696,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3009099064","doi":"10.1200/jco.19.03136","title":"Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1154,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"","keywords":"Pemetrexed; Medicine; Pembrolizumab; Lung cancer; Internal medicine; Hazard ratio; Placebo; Oncology; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Surgery; Cancer; Progressive disease; Chemotherapy; Confidence interval; Pathology; Immunotherapy; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.1020767828221736,"gpt":0.432874076965801,"spread":0.3307972941436275,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001486139,0.000292756,0.002894302,0.0002370935,0.00007703072,0.00003009373,0.0002241437,0.0003624385,0.001233588],"category_scores_gemma":[0.001549557,0.0001932932,0.0009759857,0.0007523168,0.0001774403,0.00009568721,0.00005525518,0.0007262219,0.000003560664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002986494,"about_ca_system_score_gemma":0.002985124,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007594969,"about_ca_topic_score_gemma":0.001146735,"domain_scores_codex":[0.9956742,0.0004178964,0.002791268,0.0004176742,0.0003252881,0.0003736897],"domain_scores_gemma":[0.9930788,0.003371416,0.002235746,0.000216568,0.0004679413,0.0006295579],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7553523,0.001739426,0.053486,0.0004940199,0.03524272,0.001624012,0.00251663,0.000986931,0.004237911,0.00000246827,0.03290837,0.1114092],"study_design_scores_gemma":[0.4306829,0.067333,0.1165393,0.0005425394,0.1105657,0.0003580475,0.002472692,0.1896623,0.002567722,0.00005325656,0.07796703,0.001255462],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816464,0.003319299,0.004234041,0.00881709,0.0004707316,0.001137499,0.0001293222,0.00002373774,0.0002219047],"genre_scores_gemma":[0.9803936,0.002354047,0.008489456,0.007211031,0.000796539,0.0000388597,0.00007362713,0.00004445355,0.0005983497],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3246694,"threshold_uncertainty_score":0.9996794,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2963476376","doi":"10.1016/s1470-2045(19)30388-2","title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1153,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Merck Sharp and Dohme; Les Laboratories Pierre Fabre; Merck; Meso Scale Diagnostics; Roche; British Microcirculation Society; Amgen","keywords":"Ipilimumab; Pembrolizumab; Post-hoc analysis; Open label; Medicine; Post hoc; Oncology; Internal medicine; Clinical trial; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.04835099458072202,"gpt":0.3901170919169451,"spread":0.3417660973362231,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001773703,0.0003504626,0.001847761,0.0001210652,0.0001126127,0.00005782685,0.0008537883,0.0002148316,0.0005762539],"category_scores_gemma":[0.0004221112,0.0002324201,0.000103411,0.0002704195,0.0001386342,0.0002308295,0.0001917475,0.0005255613,0.0001970639],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004988312,"about_ca_system_score_gemma":0.0004467728,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001786728,"about_ca_topic_score_gemma":0.003382797,"domain_scores_codex":[0.9963122,0.001094761,0.000905788,0.0007127291,0.0003246336,0.0006498776],"domain_scores_gemma":[0.9961311,0.001864285,0.0004195123,0.001296699,0.000146143,0.000142313],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9470787,0.005226781,0.0006090507,0.00001207628,0.0006599836,0.0001683594,0.003352647,0.00001306828,0.01499745,0.00002317721,0.0006683393,0.02719035],"study_design_scores_gemma":[0.939757,0.03466911,0.005498376,0.00006015131,0.0003012871,0.0000153112,0.004935682,0.0005993159,0.0002429391,0.00002291363,0.01362242,0.0002755338],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9764865,0.000868357,0.000001703189,0.004018663,0.001403491,0.008194679,0.000197304,0.00008014354,0.008749179],"genre_scores_gemma":[0.9952499,0.000465369,0.0003580199,0.002116715,0.000484726,0.0003376054,0.0002294415,0.00004963147,0.0007086106],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02944233,"threshold_uncertainty_score":0.9477819,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3154805493","doi":"10.1200/jco.21.00174","title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1109,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Chemotherapy; Lung cancer; Hazard ratio; Oncology; Clinical endpoint; Cancer; Surgery; Randomized controlled trial; Immunotherapy; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.08258638092140791,"gpt":0.4375760962292222,"spread":0.3549897153078143,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001154555,0.0002110467,0.001496945,0.0000862329,0.0000600933,0.00001798482,0.0001294422,0.0001491685,0.0003545884],"category_scores_gemma":[0.0003125173,0.0001213475,0.0005190231,0.0001829194,0.000200943,0.00009930445,0.00001545709,0.000566242,0.000001850256],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002846403,"about_ca_system_score_gemma":0.005502399,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005049262,"about_ca_topic_score_gemma":0.0003529413,"domain_scores_codex":[0.9974313,0.0001416858,0.001467507,0.0002694699,0.0003938848,0.0002961789],"domain_scores_gemma":[0.9961308,0.0008953079,0.001696175,0.0002236898,0.0008205129,0.0002335382],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6125771,0.004374218,0.2976188,0.0007353609,0.007841227,0.00205811,0.0004755285,0.00008759458,0.00216627,0.00003174751,0.007818514,0.06421545],"study_design_scores_gemma":[0.278909,0.06574297,0.5732024,0.0009054187,0.004845566,0.001045664,0.001434765,0.00035287,0.003987995,0.00004282724,0.06903633,0.0004942667],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856274,0.00132414,0.001045129,0.009631712,0.001020289,0.000681775,0.00001087101,0.00001116142,0.0006474874],"genre_scores_gemma":[0.9612191,0.002013221,0.02547897,0.007031133,0.001067011,0.00007821779,0.00001383413,0.00007940272,0.003019142],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3336682,"threshold_uncertainty_score":0.9761019,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3217126890","doi":"10.1200/jco.21.02229","title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1104,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Alberta Cancer Foundation","funders":"National Cancer Institute; EMD Serono; Genentech; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Amgen; Celldex Therapeutics; Array BioPharma; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Melanoma; Metastatic melanoma; Clinical trial; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.07445865462662754,"gpt":0.4172274161971886,"spread":0.342768761570561,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001055658,0.0003277401,0.002506908,0.0002027681,0.00006481287,0.00002149181,0.0002585247,0.00043083,0.0005245098],"category_scores_gemma":[0.001077225,0.0001935427,0.0004635754,0.0004831111,0.0003786954,0.0002733536,0.00007042516,0.00118742,0.00001267167],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008962182,"about_ca_system_score_gemma":0.005240915,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003377469,"about_ca_topic_score_gemma":0.002304273,"domain_scores_codex":[0.9954136,0.0003884142,0.002490149,0.000433071,0.0007879325,0.0004868311],"domain_scores_gemma":[0.9949703,0.001658206,0.00169434,0.0004778527,0.0008274578,0.0003718711],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3480144,0.00274259,0.5247004,0.00004475356,0.001160145,0.003079387,0.00009290258,0.0000122984,0.00002261021,0.000003168288,0.0002534264,0.1198738],"study_design_scores_gemma":[0.205177,0.05007746,0.7399107,0.0003620593,0.0004049891,0.0003112063,0.0001778579,0.000007200481,0.00007107936,0.000004206734,0.003285249,0.0002110323],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935613,0.0007283572,0.00005375833,0.00259199,0.001717326,0.0004093765,0.000007883538,0.00001859749,0.000911462],"genre_scores_gemma":[0.9933701,0.0006660518,0.002983546,0.0014752,0.0003203605,0.000009570471,0.00001932564,0.0000512925,0.001104556],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2152102,"threshold_uncertainty_score":0.9297158,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4285992810","doi":"10.1056/nejmoa2202809","title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1096,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck","keywords":"Pembrolizumab; Triple-negative breast cancer; Medicine; Chemotherapy; Breast cancer; Oncology; Internal medicine; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.01369630633823049,"gpt":0.2953716532372217,"spread":0.2816753468989912,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008009161,0.0001687833,0.0006310365,0.0003455083,0.00007178788,0.000004349112,0.0001590429,0.00003805655,0.004472726],"category_scores_gemma":[0.00006813902,0.0001167726,0.0001160252,0.0005239472,0.00009572727,0.0000868455,0.00002020769,0.000615827,6.910743e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000671757,"about_ca_system_score_gemma":0.0007831718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009850165,"about_ca_topic_score_gemma":0.0001481594,"domain_scores_codex":[0.9982145,0.0001184517,0.0006204891,0.0001529759,0.00065562,0.0002379606],"domain_scores_gemma":[0.9990204,0.0001254247,0.0003933515,0.0001502771,0.0001206153,0.0001899506],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1293622,0.0002134053,0.01057292,0.00005135007,0.0003850333,0.0006237005,0.007254011,0.0003546674,0.01925381,0.00002588523,0.01910716,0.8127958],"study_design_scores_gemma":[0.6348619,0.005601054,0.1755899,0.0008417667,0.0001815476,0.01001414,0.002781775,0.0001849624,0.0009405376,0.0004012611,0.168336,0.0002651846],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9302387,0.008312799,0.00006758938,0.05824164,0.001551594,0.0003704772,0.00001875636,0.00001439488,0.001184061],"genre_scores_gemma":[0.9887834,0.003152357,0.0001459043,0.003813027,0.002267319,0.0000123605,0.000004495072,0.00002686762,0.001794274],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8125306,"threshold_uncertainty_score":0.9964373,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2338494814","doi":"10.1001/jama.2016.4059","title":"Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma","year":2016,"lang":"en","type":"article","venue":"JAMA","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1062,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Ipilimumab; Pembrolizumab; Internal medicine; Melanoma; Oncology; Clinical endpoint; Clinical trial; Cohort; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.004169126603923786,"gpt":0.2152291648597737,"spread":0.2110600382558499,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002037845,0.00007626929,0.0001629952,0.00004446533,0.00002250808,0.000006152574,0.00002608601,0.00003716436,0.00004699592],"category_scores_gemma":[0.000106695,0.00003924783,0.00001992443,0.00008758447,0.00006201164,0.0001073856,0.000007785242,0.00003859053,0.000001189969],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001118573,"about_ca_system_score_gemma":0.00005806735,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000329219,"about_ca_topic_score_gemma":0.00006184404,"domain_scores_codex":[0.9993463,0.00005739792,0.0001179969,0.0001229909,0.0002402901,0.0001150429],"domain_scores_gemma":[0.9993889,0.0001463123,0.0001525973,0.0001255006,0.0001461376,0.00004051698],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09052385,0.00005786546,0.8800915,0.00001747771,0.0001226232,0.000005706669,0.0001025129,6.496965e-8,0.007527703,0.000002892064,0.0001819744,0.02136578],"study_design_scores_gemma":[0.02247303,0.001906765,0.968962,0.0002281199,0.00004185082,0.000003221136,0.0000429337,0.000001099555,0.004692279,0.000002561542,0.001576272,0.00006989023],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982867,0.0000434625,0.00001893835,0.0009910492,0.00003764572,0.0002072735,0.00002186865,0.00001579341,0.0003772182],"genre_scores_gemma":[0.99843,0.0000158941,0.0001198373,0.00009420348,0.00002129332,0.000009195484,0.000003939587,0.00001252346,0.001293184],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08887044,"threshold_uncertainty_score":0.160048,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3047081808","doi":"10.1016/j.cell.2020.07.005","title":"Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front","year":2020,"lang":"en","type":"article","venue":"Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1045,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Human Genome Research Institute; Juno Therapeutics; U.S. Food and Drug Administration; Stanford Bio-X; Defence Science and Technology Laboratory; Hamilton Health Sciences Foundation; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; University of Oxford; Parker Institute for Cancer Immunotherapy; U.S. Department of Defense; Silicon Valley Community Foundation; University of Bern; National Institute of Allergy and Infectious Diseases; Celgene; National Heart, Lung, and Blood Institute; Pfizer; Bill and Melinda Gates Foundation; National Cancer Institute; Kenneth Rainin Foundation; Cancer Research Institute; Cancer Research UK; National Science Foundation","keywords":"Biology; Colorectal cancer; Immunity; Cellular immunity; Cancer; Immunology; Cancer research; Immune system; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02454438960022445,"gpt":0.2543532474892553,"spread":0.2298088578890309,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001234383,0.0001771742,0.000254708,0.000019757,0.0001797219,0.00002547815,0.0001721881,0.00008608197,0.002503703],"category_scores_gemma":[0.00002543923,0.0001192241,0.0001408585,0.0002141074,0.0002105905,0.00004712706,0.00008468798,0.0002863763,0.0001459278],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001747862,"about_ca_system_score_gemma":0.0003188521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001032489,"about_ca_topic_score_gemma":0.0002131481,"domain_scores_codex":[0.9990461,0.00008744916,0.0002089041,0.0002322719,0.0001595782,0.0002656835],"domain_scores_gemma":[0.9994181,0.00005969671,0.00009997898,0.000214,0.00007062818,0.0001376046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002408935,0.00007563983,0.00873098,0.00009480977,0.0001223045,0.0000902294,0.001281885,0.00001175256,0.9723195,0.000002695599,0.01431712,0.0005440905],"study_design_scores_gemma":[0.002715301,0.0004958925,0.02218451,0.00004426485,0.0001170536,0.00001083678,0.0005190274,0.0002388991,0.9573169,0.000007090583,0.01617021,0.0001800529],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9833906,0.004584264,0.00002691923,0.004991029,0.0002616956,0.0004533357,0.00004156139,0.00006170192,0.006188936],"genre_scores_gemma":[0.9943894,0.0005446431,0.00002095935,0.002597738,0.00018101,0.00003020807,0.00007025444,0.00002647502,0.002139272],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01500269,"threshold_uncertainty_score":0.9984081,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2125885282","doi":"10.1200/jco.2014.58.1967","title":"Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1023,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Medicine; Carboplatin; Chemotherapy; Oncology; Human Epidermal Growth Factor Receptor 2; Triple-negative breast cancer; Internal medicine; Triple negative; Breast cancer; Cancer research; Epidermal growth factor receptor; Receptor; Pathology; Cancer; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.03804349880468626,"gpt":0.3858530708677692,"spread":0.3478095720630829,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00310928,0.0002198564,0.001578435,0.0001887143,0.00007208447,0.00001958715,0.00008915266,0.0001919636,0.00007982353],"category_scores_gemma":[0.001592087,0.0001363888,0.0001213331,0.0002020757,0.0004097018,0.0001417498,0.00002665201,0.0005538995,4.977374e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006870827,"about_ca_system_score_gemma":0.002199847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000512038,"about_ca_topic_score_gemma":0.0005512962,"domain_scores_codex":[0.9967146,0.0009280184,0.001529736,0.0002864085,0.0002701657,0.0002711051],"domain_scores_gemma":[0.9943917,0.003742065,0.001131845,0.0001141852,0.0002523782,0.000367848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.49122,0.0003557883,0.2150425,0.00006094875,0.0004959861,0.0002568779,0.003136872,0.00000294172,0.0457468,0.000008006648,0.0002733458,0.2433999],"study_design_scores_gemma":[0.03981677,0.02889312,0.9237468,0.000577693,0.0000833264,0.001598679,0.0007623758,0.00007340961,0.00305927,0.00001700168,0.001169731,0.0002018056],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929476,0.0001716644,0.0000565651,0.005848472,0.0001869841,0.0004361584,0.00001453884,0.000008487396,0.0003295739],"genre_scores_gemma":[0.986546,0.000230565,0.005833364,0.006814192,0.0004315174,0.000008821954,0.000001362264,0.00002678534,0.000107406],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7087044,"threshold_uncertainty_score":0.5561773,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2983284890","doi":"10.1200/jco.19.02107","title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1014,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Pembrolizumab; Cohort; Colorectal cancer; Tolerability; Oncology; Microsatellite instability; Irinotecan; Progression-free survival; Clinical endpoint; Oxaliplatin; Response Evaluation Criteria in Solid Tumors; Cancer; Surgery; Phases of clinical research; Adverse effect; Chemotherapy; Clinical trial; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.1353295079761783,"gpt":0.4909100416450203,"spread":0.355580533668842,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003820299,0.0002767458,0.0029882,0.0002514583,0.00005677871,0.00001508449,0.0003741621,0.0002678471,0.0004275306],"category_scores_gemma":[0.000507247,0.0001894996,0.0004894733,0.000409887,0.0002532552,0.0001882548,0.0001388788,0.0007231069,0.000008112178],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009700495,"about_ca_system_score_gemma":0.003173533,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001976298,"about_ca_topic_score_gemma":0.001504325,"domain_scores_codex":[0.9936345,0.0009558199,0.004162657,0.0004242735,0.0004630263,0.0003597058],"domain_scores_gemma":[0.9949256,0.001398471,0.002591553,0.0004199415,0.0004095693,0.0002549161],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3082857,0.2755408,0.1097114,0.0001365581,0.003245211,0.0007598472,0.003551851,0.0000302927,0.03006727,0.00001605949,0.0003678603,0.2682871],"study_design_scores_gemma":[0.391169,0.4691904,0.0983146,0.0003664415,0.001143039,0.0002591222,0.002370868,0.0001820757,0.00162534,0.00004792332,0.03506525,0.0002659979],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931742,0.001987815,0.000002274912,0.001051897,0.001609577,0.001769879,0.00003002584,0.00001132288,0.0003630102],"genre_scores_gemma":[0.996576,0.001752985,0.0006027542,0.0005501934,0.000150366,0.00003017022,0.000007178211,0.00002781316,0.0003025786],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2680211,"threshold_uncertainty_score":0.7727568,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1996863944","doi":"10.1038/ncomms6241","title":"Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","year":2014,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":995,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Natural Science Foundation of China; National Institutes of Health; Cancer Prevention and Research Institute of Texas","keywords":"Immunosuppression; Metastasis; Epithelial–mesenchymal transition; Cancer research; microRNA; CD8; Cell; Biology; PD-L1; Cancer; Immunology; Medicine; Immunotherapy; Immune system; Internal medicine; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.009676409783834309,"gpt":0.2715045231762708,"spread":0.2618281133924365,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004095939,0.0002040835,0.0004234913,0.000124482,0.0002296176,0.00002295899,0.0004919199,0.0003343593,0.0001112724],"category_scores_gemma":[0.00008038833,0.000162581,0.0001580038,0.0003011471,0.0002847158,0.000106022,0.0001705901,0.0007768333,0.000004703399],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000481803,"about_ca_system_score_gemma":0.00005928811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009104714,"about_ca_topic_score_gemma":0.00001915963,"domain_scores_codex":[0.9986004,0.0002802352,0.0004509753,0.0002404689,0.0002244767,0.0002034491],"domain_scores_gemma":[0.9974275,0.0002393444,0.0002926863,0.001692828,0.0002512927,0.00009637036],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001038697,0.0002489359,0.001512064,0.00005602635,0.0001006579,6.63024e-7,0.000322481,4.301539e-7,0.9815618,0.00005391327,0.0101105,0.004993839],"study_design_scores_gemma":[0.007854748,0.0004194962,0.05746967,0.0005740769,0.0003900101,0.00006657598,0.0002093209,0.00130731,0.8197008,0.0001640698,0.1115145,0.00032938],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8416599,0.1393583,0.0009071034,0.01358481,0.0003501789,0.001216061,0.0002140664,0.0001464704,0.002563119],"genre_scores_gemma":[0.9907873,0.002659648,0.005062938,0.001064554,0.00003671085,0.00002637105,0.0001312575,0.00002818102,0.0002030394],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.161861,"threshold_uncertainty_score":0.6629862,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2904444972","doi":"10.1200/jco.2018.78.2276","title":"T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":992,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Clinical endpoint; Cancer; Response Evaluation Criteria in Solid Tumors; Lung cancer; KRAS; Clinical trial; Phases of clinical research; Immunotherapy; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.0401353546324534,"gpt":0.3951411541431732,"spread":0.3550057995107199,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001294054,0.0002435736,0.001121799,0.0001311637,0.0001068163,0.00002710463,0.0001701554,0.0003546576,0.00008125183],"category_scores_gemma":[0.0007238489,0.0001500387,0.0001960739,0.0002254327,0.0005888455,0.0001763968,0.00005785758,0.0006798065,0.000003524588],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003071624,"about_ca_system_score_gemma":0.001788741,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009138678,"about_ca_topic_score_gemma":0.00005841186,"domain_scores_codex":[0.9963918,0.00031262,0.001944642,0.0003618621,0.0005744076,0.000414657],"domain_scores_gemma":[0.9963824,0.0006542663,0.001639057,0.0002048858,0.0007176774,0.0004017171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1924358,0.002787822,0.7453531,0.00007256705,0.0002944248,0.0004915149,0.001026454,0.00001635311,0.01375907,4.172196e-7,0.002732519,0.04102992],"study_design_scores_gemma":[0.08046674,0.03153595,0.8630435,0.000763825,0.0001553899,0.0002134701,0.0001604601,0.0001151855,0.01762388,0.00000820556,0.005725017,0.0001883279],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974234,0.0003747967,0.00002035069,0.0006126511,0.000368212,0.0008077048,0.00002037749,0.00001770096,0.000354884],"genre_scores_gemma":[0.9952334,0.0001824146,0.002682353,0.0004665231,0.001140927,0.0000315965,0.00002880925,0.00003131642,0.0002027237],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1176904,"threshold_uncertainty_score":0.6118401,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2154610258","doi":"10.4049/jimmunol.170.3.1257","title":"Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production","year":2003,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":962,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Women's Health Research Institute","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Cytokine; T cell; Cell biology; Chemistry; CD28; PD-L1; Biology; Molecular biology; Immunology; Immune system; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.01358979827491239,"gpt":0.2543486964007138,"spread":0.2407588981258014,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005566991,0.0000890373,0.0002294434,0.000117636,0.00005220856,0.00000449435,0.00006435806,0.00006819772,0.00002421991],"category_scores_gemma":[0.00008678969,0.00005389486,0.00005812979,0.000135284,0.0001486944,0.00005210981,0.000006549359,0.0002184052,0.000001023713],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004403033,"about_ca_system_score_gemma":0.00008000127,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000120489,"about_ca_topic_score_gemma":0.000001557678,"domain_scores_codex":[0.9992319,0.0001034728,0.0003335215,0.00006978971,0.0001331006,0.0001281615],"domain_scores_gemma":[0.9992356,0.0001020524,0.0003627054,0.0001405435,0.0001380094,0.00002110255],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.003350613,0.0002084856,0.000217691,0.00003538707,0.000163133,0.000002569074,0.0004554332,0.000002834739,0.9891716,0.00002634172,0.00008030064,0.006285593],"study_design_scores_gemma":[0.001736633,0.002492211,0.00487371,0.000144874,0.0001154017,0.0004711015,0.0004412806,0.00000100534,0.9870514,0.00008746776,0.002537038,0.00004784201],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940608,0.00371908,0.0000744085,0.001393145,0.0003375918,0.0001858559,4.619626e-7,0.000004892982,0.0002238243],"genre_scores_gemma":[0.995042,0.004346777,0.0002211814,0.00008909226,0.00008159548,0.000002235613,5.477694e-7,0.000008748224,0.0002078147],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006237751,"threshold_uncertainty_score":0.2197769,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2560704457","doi":"10.1016/s1470-2045(16)30624-6","title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":961,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; Juravinski Cancer Centre; University of Toronto; McMaster University","funders":"National Cancer Institute; University of Oxford","keywords":"Nivolumab; Ipilimumab; Medicine; Tolerability; Internal medicine; Lung cancer; Oncology; Cancer; Surgery; Adverse effect; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.08906368332496893,"gpt":0.4350249849294019,"spread":0.345961301604433,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008862526,0.0003071885,0.001140916,0.00006967179,0.0001797563,0.00001596689,0.0005466697,0.0001439016,0.0001251197],"category_scores_gemma":[0.00007398571,0.000165169,0.00008680905,0.0001661566,0.0001742343,0.0001143465,0.0001184997,0.0001081853,0.000008291192],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001125709,"about_ca_system_score_gemma":0.0007695555,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002656492,"about_ca_topic_score_gemma":0.006618577,"domain_scores_codex":[0.9978866,0.0001715628,0.0006808084,0.0005446956,0.0001737558,0.0005425901],"domain_scores_gemma":[0.9978306,0.0004372116,0.0004359931,0.0009868011,0.0001849954,0.0001244466],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4225556,0.01620611,0.001232039,0.0002137974,0.001505393,0.00009089513,0.005119286,0.00005194705,0.1997503,0.00001297306,0.002281403,0.3509803],"study_design_scores_gemma":[0.743577,0.09012265,0.002595145,0.0003769568,0.001264825,0.0000464164,0.001078899,0.002334652,0.06256197,0.00004216236,0.09554219,0.0004571658],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9846685,0.0009711917,0.0001392469,0.005578604,0.0005047849,0.006190637,0.0004330784,0.0000574489,0.001456516],"genre_scores_gemma":[0.9865239,0.002748437,0.001261392,0.0007417434,0.0005055752,0.001851879,0.00005593999,0.00005771888,0.006253385],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3505231,"threshold_uncertainty_score":0.6735398,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3016280944","doi":"10.3747/co.27.5223","title":"A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future","year":2020,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":953,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Immunotherapy; Cancer immunotherapy; Cancer; Radiation therapy; Standard of care; Personalized medicine; Oncology; Intensive care medicine; Internal medicine; Bioinformatics","retraction":null,"screen_n_in":null,"score":{"opus":0.1219660166743838,"gpt":0.4657855366725746,"spread":0.3438195199981908,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007153426,0.0004703754,0.002135567,0.00004941708,0.0001184573,0.00001926382,0.00129266,0.0002114777,0.0007252053],"category_scores_gemma":[0.0000818485,0.0001761757,0.001055853,0.0009543654,0.0001466362,0.00001582342,0.0002565967,0.0009560161,0.0000998537],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004111677,"about_ca_system_score_gemma":0.001286677,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002862349,"about_ca_topic_score_gemma":0.0003842358,"domain_scores_codex":[0.9969802,0.0008343111,0.000969931,0.0004995335,0.0003657145,0.0003502854],"domain_scores_gemma":[0.9972159,0.0006129166,0.000610362,0.001281495,0.0001551948,0.0001241687],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001774953,0.00005228585,0.000009267839,0.007936029,0.0005728996,0.000001982371,0.0003201834,4.170267e-8,7.823207e-7,0.000005056029,0.4044425,0.5864815],"study_design_scores_gemma":[0.0004832061,0.0003490466,0.00009118616,0.06304102,0.001759697,0.0000213214,0.00008102402,4.067612e-7,5.298637e-7,0.000002743433,0.9339917,0.0001781683],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000001813477,0.8403251,0.00001759041,0.1497057,0.004468887,0.00491887,0.0003960574,0.00003061931,0.0001353379],"genre_scores_gemma":[4.348333e-7,0.9671548,0.00002078054,0.02155661,0.008954993,0.001980407,0.0001098253,0.000075164,0.0001470038],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.5863033,"threshold_uncertainty_score":0.794049,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2743419024","doi":"10.1093/annonc/mdx286","title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","year":2017,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":921,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Rash; Nivolumab; Immunology; Pneumonitis; Cancer; Immunotherapy; Lung","retraction":null,"screen_n_in":null,"score":{"opus":0.1276813283897447,"gpt":0.4176656272783881,"spread":0.2899842988886434,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002794835,0.000484139,0.008362968,0.0003360725,0.00004181751,0.000002374903,0.0004277898,0.000601493,0.0001652097],"category_scores_gemma":[0.0004188152,0.0003508773,0.002291844,0.0002152357,0.0003262661,0.00006977034,0.0001623967,0.0004393834,0.00001198279],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001097773,"about_ca_system_score_gemma":0.0006424515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001655844,"about_ca_topic_score_gemma":0.000006503562,"domain_scores_codex":[0.9931529,0.0005903462,0.005209577,0.0003864852,0.0003509851,0.0003096932],"domain_scores_gemma":[0.9897381,0.0002885534,0.008304123,0.001173652,0.0004014175,0.00009415533],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0002315573,0.0003622414,0.00001660614,0.8680839,0.00220103,0.00003894355,0.000103299,1.118173e-8,0.0003502142,0.00001400681,0.0002940823,0.1283041],"study_design_scores_gemma":[0.001531722,0.001745649,0.0002147749,0.7563117,0.002977282,0.0003297706,0.00004907003,2.312842e-7,0.0002876173,0.000007953844,0.2363238,0.000220382],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006649307,0.9944398,9.930897e-7,0.0003555714,0.0003925106,0.003423511,0.0001192665,0.00001187695,0.0005915708],"genre_scores_gemma":[0.002406026,0.9967973,0.0000189576,0.0000722956,0.00005157338,0.0001428051,0.0001166911,0.00005342549,0.0003409328],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.2360297,"threshold_uncertainty_score":0.9998943,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}